Azole antifungal resistance today: Focus on Aspergillus

被引：38
作者：
Bowyer P. [1 ]
Moore C.B. [1 ,2 ]
Rautemaa R. [1 ,2 ,3 ,4 ]
Denning D.W. [1 ,2 ]
Richardson M.D. [1 ,2 ]
机构：
[1] Manchester Academic Health Science Centre, School of Translational Medicine, University of Manchester, Manchester
[2] University Hospital of South Manchester, Manchester
[3] Department of Oral and Maxillofacial Diseases, Helsinki University, Central Hospital, Helsinki
[4] Department of Oral Medicine, Institute of Dentistry, University of Helsinki, Helsinki
来源：
Current Infectious Disease Reports | 2011年 / 13卷 / 6期
关键词：
Aspergillus fumigatus; Azole antifungals; Resistance;
D O I：
10.1007/s11908-011-0218-4
中图分类号：
学科分类号：
摘要：
Oral triazole therapy is well established for the treatment of invasive aspergillosis (IPA), allergic aspergillosis (ABPA), and chronic pulmonary aspergillosis (CPA), and is often long-term. Resistance to triazole azole antifungal drugs in Aspergillus fumigatus is now a major clinical problem in a number of European locations, in China, Canada and the USA with particularly high frequencies from the north-west of the UK, and The Netherlands. A number of centers are reporting the continuing increasing frequency and evolution of resistance mechanisms in A. fumigatus, in both azole-naïve and patients treated with azoles. The increasing rate of resistance is of concern. A number of resistance mechanisms have been found. The biofilm modality of Aspergillus growth may have a number of therapeutic implications for aspergillosis, including antifungal resistance. Microbiological diagnosis of aspergillosis is limited by poor culture yield, leading to uncertainty about the frequency of triazole resistance. Direct resistance testing in culture-negative clinical samples may add additional insights into the prevalence of azole resistance in A. fumigatus. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：485 / 491
页数：6
相关论文
共 33 条
  • [1] Fungal Diseases in the UK - 2006
  • [2] Warnock D.W., Johnson E.M., Richardson M.D., Vickers C.F.H., Modified response to ketoconazole of Candida albicans from a treatment failure, Lancet, 1, 8325, pp. 642-643, (1983)
  • [3] Fan-Havard P., Capano D., Smith S.M., Et al., Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy, Antimicrob Agents Chemother, 35, pp. 2302-5, (1991)
  • [4] Rex J.H., Rinaldi M.G., Pfaller M.A., Resistance of Candida species to fluconazole, Antimicrob Agents Chemother, 39, pp. 1-8, (1995)
  • [5] Heald A.E., Cox G.M., Schell W.A., Bartlett J.A., Perfect J.R., Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy, AIDS, 10, 3, pp. 263-268, (1996)
  • [6] Rautemaa R., Richardson M., Pfaller M., Koukila-Kahkola P., Perheentupa J., Saxen H., Decreased susceptibility of Candida albicans to azole antifungals: A complication of long-term treatment in autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED) patients, Journal of Antimicrobial Chemotherapy, 60, 4, pp. 889-892, (2007)
  • [7] Siikala E., Rautemaa R., Richardson M., Et al., Persistent Candida albicans colonization and molecular mechanisms of azole resistance in APECED, J Antimicrob Chemother, 65, pp. 2505-13, (2010)
  • [8] Mulanovich V.E., Kontoyiannis D.P., Fungal pneumonia in patients with hematologic malignancies: Current approach and management, Curr Opin Infect Dis, 24, pp. 323-32, (2011)
  • [9] Verweij P.E., Snelders E., Kema G.H., Et al., Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use?, Lancet Infect Dis, 9, pp. 789-95, (2009)
  • [10] Richardson M.D., Warnock D.W., Fungal Infection: Diagnosis and Management, (2012)
1234